SG Sides Against Novo In Dispute Over Generics

Law360, New York (May 26, 2011, 8:30 PM EDT) -- The U.S. solicitor general said Thursday that the U.S. Supreme Court should overturn a ruling in a suit between Caraco Pharmaceutical Laboratories Ltd. and Novo Nordisk A/S that makes it easier for name-brand drugmakers to avoid generic competition.

U.S. Acting Solicitor General Neal Kumar Katyal said that a 2010 Federal Circuit ruling lets brand-name drugmakers file misleading descriptions of their patents in the U.S. Food and Drug Administration's so-called Orange Book — case law that could ultimately stop billions of dollars in legitimate generic drugs from...
To view the full article, register now.